Covered recipient · General Payments record
MEGAN S DEVINE
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$2,031.70
86 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,931.71 | 85 |
| Education | $99.99 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $397.09 | 27 |
| Boston Scientific Corporation | $360.12 | 8 |
| GENZYME CORPORATION | $190.52 | 7 |
| Actelion Pharmaceuticals US, Inc. | $178.92 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $149.18 | 3 |
| Insmed, Inc. | $147.13 | 7 |
| AstraZeneca Pharmaceuticals LP | $92.45 | 5 |
| Regeneron Healthcare Solutions, Inc. | $75.78 | 4 |
| ABBVIE INC. | $70.79 | 3 |
| VERTEX PHARMACEUTICALS INCORPORATED | $61.57 | 3 |
| Baxter Healthcare | $40.46 | 2 |
| Grifols Shared Services North America, Inc. | $35.00 | 1 |
| Integra LifeSciences Corporation | $30.73 | 1 |
| Viatris Specialty LLC | $23.54 | 1 |
| Aimmune Therapeutics, Inc. | $23.50 | 1 |
| United Therapeutics Corporation | $22.47 | 1 |
| Grifols USA, LLC | $21.80 | 1 |
| Electromed, Inc. | $20.77 | 2 |
| Merck Sharp & Dohme LLC | $20.47 | 1 |
| Mallinckrodt Hospital Products Inc. | $18.86 | 1 |
| HOSPIRA, INC. | $18.47 | 1 |
| Paratek Pharmaceuticals, Inc. | $16.58 | 1 |
| Philips North America LLC | $15.50 | 1 |
Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MEGAN S DEVINE
NPI 1255541108 · CMS profile ID 283573
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
TYLER, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1255541108?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MEGAN S DEVINE, NPI 1255541108, CMS profile ID 283573. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255541108?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). MEGAN S DEVINE, NPI 1255541108, CMS profile ID 283573. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255541108?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- MEGAN S DEVINE, NPI 1255541108, CMS profile ID 283573, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1255541108?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
86 matching records · $2,031.70 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–86 of 86.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $14.35 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190842797 | CMS |
| GlaxoSmithKline, LLC. | $11.57 | 06/27/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191507226 | CMS |
| Boston Scientific Corporation | $94.41 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181193382 | CMS |
| Boston Scientific Corporation | $8.64 | 06/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181193378 | CMS |
| GlaxoSmithKline, LLC. | $15.34 | 06/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190692208 | CMS |
| GlaxoSmithKline, LLC. | $14.15 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190763437 | CMS |
| GlaxoSmithKline, LLC. | $4.54 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191168383 | CMS |
| GlaxoSmithKline, LLC. | $15.12 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190338395 | CMS |
| Grifols Shared Services North America, Inc. | $35.00 | 05/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249580840 | CMS |
| VERTEX PHARMACEUTICALS INCORPORATED | $19.45 | 05/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213878474 | CMS |
| Boston Scientific Corporation | $6.45 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181193380 | CMS |
| Insmed, Inc. | $17.95 | 05/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186267202 | CMS |
| GlaxoSmithKline, LLC. | $8.70 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191836510 | CMS |
| Baxter Healthcare | $24.60 | 05/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181701221 | CMS |
| Baxter Healthcare | $15.86 | 04/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1181701219 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.33 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207253869 | CMS |
| Viatris Specialty LLC | $23.54 | 04/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238504715 | CMS |
| Merck Sharp & Dohme LLC | $20.47 | 04/24/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238325256 | CMS |
| GENZYME CORPORATION | $31.78 | 04/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233422592 | CMS |
| GlaxoSmithKline, LLC. | $14.00 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1191224298 | CMS |
| Aimmune Therapeutics, Inc. | $23.50 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1249684528 | CMS |
| GENZYME CORPORATION | $30.43 | 03/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233422572 | CMS |
| GlaxoSmithKline, LLC. | $10.55 | 03/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190693552 | CMS |
| GlaxoSmithKline, LLC. | $15.31 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190639507 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.38 | 03/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1207092169 | CMS |
| GENZYME CORPORATION | $20.83 | 02/26/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1233422556 | CMS |
| ABBVIE INC. | $20.59 | 02/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201758192 | CMS |
| GlaxoSmithKline, LLC. | $15.79 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190849024 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.84 | 02/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1206926839 | CMS |
| GlaxoSmithKline, LLC. | $17.00 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190799484 | CMS |
| Actelion Pharmaceuticals US, Inc. | $32.32 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1174309377 | CMS |
| Electromed, Inc. | $2.16 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224588664 | CMS |
| Electromed, Inc. | $18.61 | 01/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1224588669 | CMS |
| VERTEX PHARMACEUTICALS INCORPORATED | $19.52 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213890315 | CMS |
| Philips North America LLC | $15.50 | 01/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1232601638 | CMS |
| GlaxoSmithKline, LLC. | $13.98 | 01/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1190830110 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $194,337.54 | 92 |
| PY2024 | Principal investigator | $69,784.00 | 11 |
| PY2023 | Principal investigator | $26,498.00 | 4 |
| PY2021 | Principal investigator | $5,599.80 | 1 |
| PY2020 | Principal investigator | $3,700.00 | 2 |
| PY2019 | Principal investigator | $17.20 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
92 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 12/17/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620042 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 12/17/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620044 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.32 | 12/17/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620046 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.00 | 12/17/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620048 |
| Principal investigator 2 | Mannkind Corporation | $10,000.00 | 12/10/2025 | Non-covered Recipient Entity UT HEALTH SCIENCE CENTER | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898690 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,151.80 | 12/05/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220795803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 12/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620028 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 12/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620030 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 12/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620032 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.94 | 12/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620034 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 12/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 12/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670254 |
| Principal investigator 1 | Verona Pharma, Inc. | $1,500.00 | 12/01/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH | Verona | No dispute reported | 06/30/2026 | 1232891417 |
| Principal investigator 1 | Verona Pharma, Inc. | $736.54 | 12/01/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH | Verona | No dispute reported | 06/30/2026 | 1232891419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.50 | 11/28/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620050 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 11/28/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620052 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.21 | 11/28/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620054 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.87 | 11/20/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620002 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.72 | 11/20/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620004 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $0.70 | 11/20/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620006 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.60 | 11/20/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620008 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.39 | 11/20/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620010 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 11/19/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620036 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.32 | 11/19/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620038 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 11/19/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620040 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 11/19/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 11/19/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.41 | 11/19/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670260 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,668.10 | 11/17/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220795801 |
| Principal investigator 1 | Verona Pharma, Inc. | $11,654.77 | 11/07/2025 | Non-covered Recipient Entity THE UNIVERSITY OF TEXAS HEALTH | Verona | No dispute reported | 06/30/2026 | 1232891413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 11/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620020 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 11/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620022 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 11/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620024 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.94 | 11/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620026 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 11/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 11/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670250 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,194.00 | 10/27/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226120392 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,382.30 | 10/22/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220795799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.94 | 10/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620012 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 10/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620014 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 10/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620016 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 10/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620018 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 10/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 10/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670246 |
| Principal investigator 1 | Genentech, Inc. | $1,250.00 | 10/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562922 |
| Principal investigator 1 | Genentech, Inc. | $3,300.00 | 10/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562925 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $420.00 | 09/15/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226120381 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.94 | 09/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619972 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 09/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619996 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 09/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619998 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 09/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220620000 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 09/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 09/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670240 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $47,704.00 | 08/25/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis | No dispute reported | 06/30/2026 | 1226120384 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.94 | 08/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619978 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 08/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619986 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 08/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619988 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 08/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619990 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619992 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $300.00 | 08/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619994 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 08/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 08/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 07/28/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $799.00 | 07/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619970 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $32.94 | 07/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619974 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $120.93 | 07/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619976 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.29 | 07/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619980 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.08 | 07/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619982 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $94.42 | 07/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619984 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 07/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 07/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670232 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,000.00 | 06/25/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220795795 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $203.88 | 06/05/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220795797 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,000.00 | 06/04/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids | No dispute reported | 06/30/2026 | 1185546795 |
| Principal investigator 1 | Verona Pharma, Inc. | $3,500.00 | 06/02/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Verona | No dispute reported | 06/30/2026 | 1232891835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $785.00 | 06/01/2025 | Non-covered Recipient Entity UNIV OF TEXAS HSC ATTY TYLER | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) | No dispute reported | 06/30/2026 | 1220619968 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.82 | 06/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670226 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.11 | 06/01/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220670228 |
| Principal investigator 1 | Genentech, Inc. | $1,025.00 | 05/16/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562914 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,928.70 | 05/06/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM) | No dispute reported | 06/30/2026 | 1220795793 |
| Principal investigator 1 | Genentech, Inc. | $4,100.00 | 04/25/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562910 |
| Principal investigator 1 | Verona Pharma, Inc. | $13,000.00 | 04/25/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Verona | No dispute reported | 06/30/2026 | 1232891831 |
| Principal investigator 1 | Genentech, Inc. | $1,025.00 | 04/11/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562906 |
| Principal investigator 1 | Genentech, Inc. | $1,025.00 | 04/04/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562917 |
| Principal investigator 1 | Genentech, Inc. | $2,050.00 | 03/21/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562871 |
| Principal investigator 1 | Genentech, Inc. | $1,025.00 | 03/07/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562855 |
| Principal investigator 1 | Genentech, Inc. | $500.00 | 02/26/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562863 |
| Principal investigator 1 | Genentech, Inc. | $1,025.00 | 02/05/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562867 |
| Principal investigator 2 | Mannkind Corporation | $22,500.00 | 02/05/2025 | Non-covered Recipient Entity UT HEALTH SCIENCE CENTER | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898426 |
| Principal investigator 2 | Mannkind Corporation | $3,500.00 | 02/05/2025 | Non-covered Recipient Entity UT HEALTH SCIENCE CENTER | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | No dispute reported | 06/30/2026 | 1250898428 |
| Principal investigator 1 | Genentech, Inc. | $3,636.00 | 01/29/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562859 |
| Principal investigator 1 | Genentech, Inc. | $8,200.00 | 01/13/2025 | Covered Recipient Teaching Hospital Ut Health Center At Tyler | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211562874 |